. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Cancer Epidemiol. 2011 Feb 10;35(6):569–573. doi: 10.1016/j.canep.2011.01.006

Table 3.

Baseline and 12-Month Follow-up Prolactin Geometric Means (ng/mL) by Adherence

		Baseline	12-mos Follow-up
		Mean (95% CI)	Mean (95% CI)	Change (%)	P¹	P²
Increase in Min/Wk
	Controls	7.8 (6.7, 9.1) (n=51)	7.8 (6.9, 8.8) (n=49)	0 (0.0)	Ref	N/A
	Exercisers
	<250 Min/Wk	6.8 (5.4, 8.6) (n=15)	8.2 (6.5, 10.3) (n=13)	1.4 (20.6)	0.28	Ref
	250-300 Met Min/Wk	6.1 (4.7, 7.9) (n=10)	6.6 (5.4, 7.9) (n=10)	0.5 (8.2)	0.71	0.32
	300+ Met Min/Wk	8.3 (6.7, 10.3) (n=24)	8.4 (6.9, 10.2) (n=24)	0.1 (1.2)	0.73	0.11
					(p_trend = 0.70)	(p_trend = 0.15)

Increase in steps/day
	Controls	7.8 (6.7, 9.1) (n=51)	7.8 (6.9, 8.8) (n=49)	0 (0.0)	Ref	N/A
	Exercisers
	<1760 steps/day	7.1 (5.5, 9.1) (n=18)	7.7 (6.3, 9.4) (n=18)	0.6 (8.5)	0.63	Ref
	1760-3519 steps/day	8.1 (5.3, 12.3) (n=8)	9.0 (5.7, 14.4) (n=8)	0.9 (11.1)	0.29	0.90
	3520+ steps/day	7.3 (5.8, 9.2) (n=15)	7.9 (6.4, 9.6) (n=15)	0.6 (8.2)	0.77	0.86
					(p_trend = 0.33)	(p_trend = 0.93)

Change in VO₂ max
	Controls	7.8 (6.7, 9.1) (n=51)	7.8 (6.9, 8.8) (n=49)	0 (0.0)	Ref	N/A
	Exercisers
	Decreased or <5% increase	7.2 (5.4, 9.7) (n=15)	8.3 (6.5, 10.6) (n=15)	1.1 (15.3)	0.35	Ref
	Increased 5% - 15%	7.1 (5.2, 9.5) (n=15)	7.1 (6.1, 8.2) (n=15)	0 (0.0)	0.94	0.42
	Increased < 15%	7.3 (6.0, 8.7) (n=14)	7.7 (5.9, 9.9) (n=14)	0.4 (5.5)	0.57	0.43
					(p_trend = 0.70)	(p_trend = 0.46)

Testing a difference between the change from baseline to 12 months in the exercise group versus controls

Testing a difference between the change from baseline to 12 months in middle or high exercise adherence groups versus low adherence group (controls excluded)